A human anti-Pseudomonas aeruginosa serotype O6ad immunoglobulin G1 expressed in transgenic tobacco is capable of recruiting immune system effector function in vitro

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3322-3328

  McLean, Michael D ^a   Almquist, Kurt C ^a   Niu, Yongfing ^a   Kimmel, Rhonda ^b   Lai, Zengzu ^b,c   Schreiber, John R ^b,c   Hall, J Christopher ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; COMPLEMENT; GLYCAN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; MANNOSE; PROTEIN NCOI; PROTEIN NOTI; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; GENETIC ENGINEERING; GENETIC TRANSFORMATION; IMMUNE SYSTEM; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPSONIZATION; OPSONOPHAGOCYTOSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS AERUGINOSA SEROTYPE O6AD; SEROTYPING; TOBACCO;

ANTIBODIES, MONOCLONAL; ENDOPLASMIC RETICULUM; GENETIC VECTORS; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; MANNOSE; MOLECULAR SEQUENCE DATA; NEUTROPHILS; OPSONIN PROTEINS; PHAGOCYTOSIS; PLANTS, GENETICALLY MODIFIED; POLYSACCHARIDES; PSEUDOMONAS AERUGINOSA; RECOMBINANT PROTEINS; TOBACCO;

EID: 35948970963     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00366-07     Document Type: Article

References (56)

1. Almquist, K. C., M. D. McLean, Y. Niu, G. Byrne, F. C. Olea-Popelka, C. Murrant, J. Barclay, and J. C. Hall. 2006. Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant Ab in transgenic tobacco. Vaccine 24:2079-2086.
2. Almquist, K. C., Y. Niu, M. D. McLean, F. Mena, K. Yau, K. Brown, J. E. Brandle, and J. C. Hall. 2004. Immunomodulation confers herbicide resistance in plants. Plant Biotechnol. J. 2:189-197.
3. Andersen, D. C., and D. E. Reilly. 2004. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 15:456-462.
4. Arbabi-Ghahroudi, M., J. Tanha, and R. MacKenzie. 2005. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 24:501-519.
5. Bakker, H., G. J. Rouwendal, A. S. Karnoup, D. E. Florack, G. M. Stoopen, J. P. Helsper, R. van Ree, I. van Die, and D. Bosch. 2006. An antibody produced in tobacco expressing a hybrid beta-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. Proc. Natl. Acad. Sci. USA 103:7577-7582.
6. Berger, M., T. M. Norvell, M. F. Tosi, S. N. Emancipator, M. W. Konstan, and J. R. Schreiber. 1994. Tissue-specific Fc gamma and complement receptor expression by alveolar macrophages determines relative importance of IgG and complement in promoting phagocytosis of Pseudomonas aeruginosa. Pediatr. Res. 35:68-77.
7. Brodzik, R., M. Glogowska, K. Bandurska, M. Okuliez, D. Deka, K. Ko, J. van der Linden, J. H. W. Leusen, N. Pogrebnyak, M. Golovkin, A. Steplewski, and H. Koprowski. 2006. Plant-derived anti-Lewis Y MAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc. Natl. Acad. Sci. USA 103:8804-8809.
8. Bruggemann, M., G. T. Williams, C. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166:1351-1361.
9. Burton, D. R. 2002. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2:706-713.
10. Cabanes-Macheteau, M., A. C. Fitchette-Laine, C. Joutelier-Bourhis, C. Lange, N. C. Vine, J. K. C. Ma, P. Lerouge, and L. Faye. 1999. N-glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 9:365-372.
11. Chargelegue, D., N. C. Vine, C. J. van Dolleweerd, P. M. Drake, and J. K. Ma. 2000. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 9:187-194.
12. Co, M. S., and C. Queen. 1991. Humanized antibodies for therapy. Nature 351:501-502.
13. Cox, K. M., J. D. Sterling, J. T. Regan, J. T. Gasdaska, K. K. Frantz, C. G. Peele, A. Black, D. Passmore, C. Moldovan-Loomis, H. Srinivasan, S. Cuison, P. M. Cardarelli, and L. F. Dickey. 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat. Biotechnol. 24:1591-1597.
14. Dangl, J. L., T. G. Wensel, S. L. Morrison, L. Stryer, L. A. Herzenberg, and V. T. Oi. 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 7:1989-1994.
15. Datla, R. S. S., J. K. Hammerlindl, B. Panchu, L. E. Pelcher, and W. Keller. 1992. Modified binary plant transformation vectors with the wild-type gene encoding NPTII. Gene 211:383-384.
16. Elbein, A. D. 1979. The role of the lipid-linked saccharides in the biosynthesis of complex carbohydrates. Annu. Rev. Plant Physiol. 30:239-272.
17. Elbers, I. J. W., G. M. Stoopen, H. Bakker, L. H. Stevens, M. Bardor, J. W. Molthoff, W. J. R. M. Jordi, D. Bosch, and A. Lommen. 2001. Influence of growth conditions and developmental stage on N-glycan heterogeneity of transgenic immunoglobulin G and endogenous proteins in tobacco leaves. Plant Physiol. 126:1314-1322.
18. Ellison, J. W., B. J. Berson, and L. E. Hood. 1982. The nucleotide sequence of a human immunoglubuin C Gamma1 gene. Nucleic Acids Res. 10:4071-4079.
19. Gomord, V., C. Sourrouille, A. C. Fitchette, M. Bardor, S. Pagny, P. Lerouge, and L. Faye. 2004. Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge. Plant Biotechnol. J. 2:83-100.
20. Gottleib, P. D., B. A. Cunningham, U. Rutishauser, and G. M. Edelman. 1970. The covalent structure of a human gamma G-immunoglobulin. VI. Amino acid sequence of the LC. Biochemistry 9:3155-3161.
21. Hatano, K., S. Boisot, D. DesJardins, D. G. Wright, J. Brisker, and G. B. Pier. 1994. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. Infect. Immun. 62:3608-3616.
22. Hemachandra, S., K. Kamboj, J. Copfer, G. Pier, L. L. Green, and J. R. Schreiber. 2001. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal Pseudomonas sepsis. Infect. Immun. 69:2223-2229.
23. Hirschberg, C. B., and M. D. Snider. 1987. Topography of glycosylation in the rough endoplasmic reticulum and Golgi apparatus. Annu. Rev. Biochem. 56:63-87.
24. Huether, C. M., O. Lienhart, A. Baur, C. Stemmer, G. Gorr, R. Reski, and E. L. Decker. 2005. Glyco-engineering of moss lacking plant-specific sugar residues. Plant Biol. 7:292-299.
25. Jungbauer, A., C. Tauer, M. Reiter, M. Purtscher, E. Wenisch, F. Steindl, A. Buchacher, and H. Katinger. 1989. Comparison of protein A, protein G and copolymerised hydroxyapatite for the purification of human monoclonal antibodies. J. Chromatogr. 476:257-268.
26. Kermode, A. R. 1996. Mechanisms of intracellular protein transport and targeting in plant cells. Crit. Rev. Plant Sci. 15:285-423.
27. Knirel, Y. 1990. Polysaccharide antigens of Pseudomonas aeruginosa. Crit. Rev. Microbiol. 17:273-303.
28. Ko, K., Z. Steplewski, M. Glogowska, and H. Koprowski. 2005. Inhibition of tumor growth by plant-derived MAb. Proc. Natl. Acad. Sci. USA 102:7026-7030.
29. Ko, K., Y. Tekoah, P. M. Rudd, D. J. Harvey, R. A. Dwek, S. Spitsin, C. A. Hanlon, C. Rupprecht, B. Dietzschold, M. Golovkin, and H. Koprowski. 2003. Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc. Natl. Acad. Sci. USA 100:8013-8018.
30. Lai, Z., R. Kimmel, S. Petersen, S. Thomas, G. Pier, B. Bezabeh, R. Luo, and J. R. Schreiber. 2005. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23:3264-3271.
31. Ma, J. K., B. Y. Kikmat, K. Wycoff, N. D. Vine, D. Chargelegue, L. Yu, N. B. Hein, and T. Lehner. 1998. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunothreapy in humans. Nat. Med. 4:601-606.
32. Mariani, G., and W. Strober. 1990. Immunoglobulin metabolism, p. 94-177. In H. Metzger (ed.), Fc receptors and the action of antibodies. ASM Press, Washington, DC.
33. Mendez, M. J., L. L. Green, J. R. Corvalan, X. C. Jia, C. E. Maynard-Currie, X. D. Yang, M. L. Gallo, D. M. Louie, D. V. Lee, K. L. Erickson, J. Luna, C. M. Roy, H. Abderrahim, F. Kirschenbaum, M. Noguchi, D. H. Smith, A. Fukushima, J. F. Hales, S. Klapholz, M. H. Finer, C. G. Davis, K. M. Zsebo, and A. Jakobovits. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15:146-156.
34. Miki, B., S. G. McHugh, H. Labbe, T. Ouellet, J. H. Tolman, and J. E. Brandle. 1999. Transgenic tobacco: gene expression and applications. Biotechnol. Agric. For. 45:336-354.
35. Nuttall, J., J. K.-C. Ma, and L. Frigerio. 2005. A functional antibody lacking N-linked glycans is efficiently folded, assembled and secreted by tobacco mesophyll protoplasts. Plant Biotechnol. J. 3:497-504.
36. Olea-Popelka, F. C., M. D. McLean, J. Horsman, K. Almquist, J. E. Brandle, and J. C. Hall. 2005. Increasing expression of an anti-picloram single-chain variable fragment (scFv) Ab and resistance to picloram in transgenic tobacco (Nicotiana tabacum). J. Agric. Food Chem. 53:6683-6690.
37. Paccalet, T., M. Bardor, C. Rihouey, F. Delmas, C. Chevalier, M.-A. D'Aoust, L. Faye, L. Vezina, V. Gomord, and P. Lerouge. 2007. Engineering of a sialic acid synthesis pathway in transgenic plants by expression of bacterial Neu5Ac-synthesizing enzymes. Plant Biotechnol. J. 5:16-25.
38. Preston, M. J., A. A. Gerceker, R. E. Reff, and G. B. Pier. 1988. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide. Infect. Immun. 66:4137-4142.
39. Rosenberg, A. 1995. Biology of sialic acids. Plenum Press, New York, NY.
40. Samac, D. A., C. M. Hironaka, P. E. Yallaly, and D. M. Shah. 1990. Isolation and characterization of the genes encoding basic and acidic chitinase in Arabidopsis thaliana. Plant Physiol. 93:907-914.
41. Scheinberg, D. A., and P. B. Chapman. 1995. Therapeutic applications of monoclonal antibodies for human disease, p. 45-105. In J. R. Birch and E. S. Lennox (ed.), Monoclonal antibodies: principles and applications. Wiley-Liss, New York, NY.
42. Schilperoort, R. A., and S. B. Gelvin. 1995. Plant molecular biology manual, 2nd ed. Kluwer Academic Publishers, GB, New York, NY.
43. Schouten, A., J. Roosien, F. A. van Engelen, G. A. de Jong, A. W. Borst-Vrenssen, J. F. Zilverentant, D. Bosch, W. J. Stiekema, F. J. Gommers, A. Schots, and J. Bakker. 1996. The C-terminal KDEL sequence increases the expression level of a single-chain Ab designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. Plant Mol. Biol. 30:781-793.
44. Schreiber, J. R., L. J. N. Cooper, S. Diehn, P. A. Dalhhauser, M. F. Tosi, D. D. Glass, M. Patawaran, and N. S. Greenspan. 1993. Variable region-identical monoclonal Abs of different IgG subclasses directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently. J. Infect. Dis. 167:221-226.
45. Schreiber, J. R., K. L. Nixon, M. F. Tosi, G. B. Pier, and M. B. Patawaran. 1991. Anti-idiotype-induced, lipopolysaccharide specific Ab response to Pseudomonas aeruginosa. II. Isotype and functional activity of the anti-idiotype-induced Abs. J. Immunol. 146:188-193.
46. Schreiber, J. R., G. B. Pier, M. Grout, K. Nixon, and M. Patawaran. 1991. Induction of opsonic Abs to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal Ab. J. Infect. Dis. 164:507-514.
47. Shah, M. M., K. Fujiyama, C. R. Flynn, and L. Joshi. 2003. Sialylated endogenous glycoconjugates in plant cells. Nat. Biotechnol. 21:1470-1471.
48. Sriraman, R., M. Bardor, M. Sack, C. Vaquero, L. Faye, R. Fischer, R. Finnern, and P. Lerouge. 2004. Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-α(1,3)-fucose residues. Plant Biotechnol. J. 2:279-287.
49. Stoger, E., M. Sack, L. Nicholson, R. Fischer, and P. Christou. 2005. Recent progress in plantibody technology. Curr. Pharm. Des. 11:2439-2457.
50. Timmermans, M., P. Maliga, J. Vieira, and J. Messing. 1990. The pFF plasmids: cassettes utilising CaMV sequences for expression of foreign genes in plants. J. Biotechnol. 14:333-344.
51. Triguero, A., G. Cabrera, J. A. Cremata, C.-T. Yuen, J. Wheeler, and N. I. Ramirez. 2005. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol. J. 3:449-457.
52. Varki, A. 1999. Discovery and classification of animal lectins, p. 333-343. In A. Varki, R. Cummings, J. Esko, H. Freeze, G. Hart, and J. Marth (ed.), Essentials of glycobiology. Cold Spring Harbor Laboratory Press, Cold Spring Harborn, NY.
53. Weir, A. N. C., A. Nesbitt, A. P. Chapman, A. G. Popplewell, P. Antoniw, and A. D. G. Lawson. 2002. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30:512-516.
54. Wright, A., and S. L. Morrison. 1997. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 15:26-32.
55. Wurm, F. W. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22:1393-1398.
56. Zeitlin, L., S. S. Olmsted, T. R. Moench, M. S. Co, B. J. Martinell, V. M. Paradkar, D. R. Russell, C. Queen, R. A. Cone, and K. J. Whaley. 1998. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat. Biotechnol. 16:1361-1364.